We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App





World's First Inhalable COVID-19 Vaccine Approved in China

By HospiMedica International staff writers
Posted on 06 Sep 2022
Print article
Image: The Convidecia Air inhalable COVID-19 vaccine has been approved for use as a booster dose (Photo courtesy of Pexels)
Image: The Convidecia Air inhalable COVID-19 vaccine has been approved for use as a booster dose (Photo courtesy of Pexels)

CanSino Biologics Inc. (Tianjin, China) has received approval from the National Medical Products Administration of China (NMPA) for Convidecia Air, its recombinant COVID-19 vaccine (Adenovirus Type 5 Vector) for inhalation to be used as a booster dose.

Utilizing the same adenovirus vector technological platform as the company's intramuscular version Convidecia, Convidecia Air provides a non-invasive option that uses a nebulizer to change liquid into an aerosol for inhalation through the mouth. Convidecia Air is needle-free and can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath. Studies have indicated that Convidecia Air can induce strong humoral, cellular and mucosal immunity to achieve triple protection and effectively contain the infection and spread of the virus.

Related Links:
CanSino Biologics Inc. 

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Suction Electrode System
Strässle
New
Multi-Parameter Patient Monitor
S90

Print article

Channels

Critical Care

view channel
Image: EKG home screen (Photo courtesy of Bluhm Cardiovascular Institute)

Wearables Could Reduce Need for Continuous Blood Thinners in Patients with Atrial Fibrillation

Atrial fibrillation (AFib) is the most prevalent heart arrhythmia, affecting over 5 million individuals in the United States, with projections suggesting that number could rise to 12.1 million by 2030.... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.